Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

• Drug: Lersivirine Immediate-Release (fasted)
  
  Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
• Drug: Lersivirine Modified-Release #1 (fasted)
  
  Single 500 mg dose of Lersivirine Modified-Release Tablet #1
• Drug: Lersivirine Modified-Release #2 (fasted)
  
  Single 500 mg dose of Lersivirine Modified-Release Tablet #2
• Drug: Lersivirine Modified-Release #3 (fasted)
  
  Single 500 mg dose of Lersivirine Modified-Release Tablet #3
• Drug: Lersivirine Modified-Release (fed)
  
  Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.

Inclusion Criteria:

• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening;
• Treatment with an investigational drug within 60 days (or as determined by the local requirement, whichever is longer) or 5 half-lives preceding the first dose of study medication;
• Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.